Astrazeneca's (AZN) Imfinzi in combination with chemotherapy has been approved in the European Union for the treatment of adults with operable non-small cell lung cancer.
The specific indication for the treatment of patients at high risk of recurrence and no epidermal growth factor receptor mutations or anaplastic lymphoma kinase rearrangements, the company said Friday.
Under the treatment plan, patients are treated with the drug, also known as durvalumab, in combination with neoadjuvant chemotherapy before surgery and as an adjuvant monotherapy after surgery, the company said.
The European Commission approval follows a positive opinion issued by the Committee for Medicinal Products for Human Use as well as results from a clinical trial in which the drug resulted in a 32% reduction in recurrence, progression, or death vs patients treated with chemotherapy alone, the company said.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。